Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives

Major breakthroughs have been achieved in the management of metastatic pancreatic ductal adenocarcinoma (PDAC) with FOLFIRINOX (5-fluorouracil + irinotecan + oxaliplatin) and gemcitabine plus nab-paclitaxel approved as a first-line therapy, although the prognosis is still poor. At progression, patie...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ther Adv Med Oncol
Asıl Yazarlar: Lellouche, Lisa, Palmieri, Lola-Jade, Dermine, Solène, Brezault, Catherine, Chaussade, Stanislas, Coriat, Romain
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2021
Konular:
Advances in Treatment of Lung Cancer Patients with Targetable Mutations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264726/
https://ncbi.nlm.nih.gov/pubmed/34285720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211018539
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller